[Federal Register: July 6, 2005 (Volume 70, Number 128)]
[Notices]
[Page 38939-38944]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr06jy05-115]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Augmenting Laboratory Outcomes in HIV Assessment (ALOHA)
Announcement Type: Supplemental (04017).
Funding Opportunity Number: AA120.
Catalog of Federal Domestic Assistance Number: 93.944.
Key Dates:
Application Deadline: August 5, 2005.
I. Funding Opportunity Description
Authority: This program is authorized under sections 317(k)(2) and
318b of the Public Health Service Act (42 U.S.C. Sections 247b(k)(2)
and 247c), as amended.
Purpose: CD4+ T-lymphocyte (CD4) and viral load (VL) tests are used
to stage disease and, when opportunistic infections (OI) are present,
to guide therapeutic decisions. Because CD4 and VL testing should be
performed throughout the course of HIV disease, reporting of these lab
tests has been used as a marker for whether HIV-infected persons are
receiving healthcare. Augmenting Laboratory Outcomes in HIV Assessment
(ALOHA) will augment routine HIV/AIDS surveillance data collection for
the purpose of assessing the completeness and validity of laboratory
(i.e., CD4 count and VL) and OI information. This will be accomplished
by the following:
1. Assessing the stage of HIV disease at initial diagnosis among a
cohort of newly diagnosed HIV-infected persons, over the age of 13,
using routine and augmented laboratory and clinical information.
2. Better characterizing CD4 count and VL, and correlating this
laboratory information with available data on OIs. If, after complete
enumeration of lab and OI information, OIs add little to nothing to
help stage HIV disease, then future surveillance practices may be
streamlined.
3. Identifying surveillance practices (e.g., laboratory reporting
requirements, electronic lab reporting, and program policies or
organization) that affect the completeness and accuracy of surveillance
laboratory data.
4. Assessing lab reporting as a marker for access and adherence to
care following HIV diagnosis.
5. Identifying correlates for not being in care, as indicated by
the presence or absence of laboratory reports.
6. Systematically evaluating the availability of clinical and
laboratory data on the prevalence of common co-morbid conditions (e.g.,
hepatitis B, hepatitis C, tuberculosis, and cancer) that are associated
with risk factors for HIV infection and influence the clinical course
of HIV disease. Data on these conditions will be compared to levels of
CD4 and VL to assess the effects of co-morbid conditions on levels of
immunosuppression at the time of HIV diagnosis.
A variety of HIV/AIDS reporting areas with different surveillance
practices and procedures will be sought for ALOHA. This project will
attempt to include an area that currently warehouses lab results,
specifically CD4, in a separate lab results database, and does not
report this information to the national HIV/AIDS surveillance system.
The completeness of reporting for CD4 results will be assessed to
determine if these reports truly indicate access to care. This
proportion has not been reliably estimated by national surveillance
data. Some reporting areas report a high proportion (greater than 75
percent) of newly diagnosed cases with CD4 and/or VL results within 12
months of diagnosis.
The factors that contribute to the ability of lower morbidity areas
to report completely has not been fully examined, but may be due to
their ability to conduct active case finding and medical record
abstraction. These practices may have national surveillance policy
implications. Since lab reporting data is critical to the expectations
of the Morbidity Monitoring Project (MMP), an area will be sought to
provide validation of lab reporting as a marker for receiving health
care, and to collect information about reasons for no lab testing and
the inability to link a person to care.
Lastly, ALOHA will include at least one area that will match its
HIV/AIDS case registry to infectious disease databases to identify,
apart from medical record review, OIs that occurred six months before
and after HIV diagnosis. Examples of these databases include the
National Electronic Disease Surveillance System (NEDSS); cancer,
hepatitis or tuberculosis registries; or prescription medication
databases (e.g., Medicaid or AIDS Drug Assistance Program).
As part of this project, participating areas will conduct their
usual surveillance activities for information on CD4 and VL lab results
and OIs. These activities include active case surveillance, medical
record review and data extraction for newly diagnosed cases (over the
age of 13). When no lab result is received by the HIV/AIDS surveillance
program, ongoing active case follow-up will be needed to determine case
disposition and record specific categorical information, such as
[[Page 38940]]
the source of CD4 and OI results and, alternatively, reasons for no CD4
testing (e.g., lost to follow-up, did not return for HIV test results,
etc). Surveillance information will be entered into the national HIV/
AIDS surveillance system and uploaded monthly to CDC; ancillary data
will be sent to CDC without personal identifiers.
Annual reported cases to CDC will be used as an eligibility
criterion. Eligible areas are restricted to those submitting HIV data
to CDC because this project is an evaluation of data included in the
national HIV/AIDS reporting system, which includes only those
surveillance data collected in confidential name-based systems, and
because HIV (not AIDS) cases are currently more likely to be missing
CD4 information. Because a limited number of sites (approximately five
to seven sites) will be funded, racial and ethnic diversity of cases
among each of the participating sites will be required to ensure a
measure of representation of national data.
This program addresses the ``Health People 2010'' focus area of
HIV. Measurable outcomes of the program will be in alignment with one
(or more) of the following performance goal(s) for the National Center
for HIV, STD, and TB Prevention (NCHSTP): Strengthen the capacity
nationwide to monitor the epidemic, develop and implement effective HIV
prevention interventions, and evaluate prevention programs.
Activities: Awardee activities for this program are as follows:
1. Accurately linking incoming lab results to all HIV and AIDS
cases or an agreed upon sample, over the age of 13, in the local HIV/
AIDS registry, and transmitting that information to the national HIV/
AIDS surveillance system for the duration of ALOHA.
2. Conducting active surveillance and medical record abstraction,
following a protocol developed in collaboration with CDC, of all cases
or the agreed upon sampled cases. A minimum of 500 diagnosed HIV/AIDS
cases annually, of which 300 cases were initially diagnosed with HIV
(not AIDS), will be prospectively followed for a period of time (to be
determined through collaborative development of a protocol). This
protocol will include the collection of CD4 and VL results, OIs, and
ancillary information on data collection forms.
3. Conducting active, ongoing follow-up of cases without any CD4 or
VL results following diagnosis. Identifiable reasons for lack of
linkage or failure to access health care will be sought from medical
records and recorded on project data collection forms. No interview of
cases will occur as part of this follow-up.
4. Documenting methods of linking lab results to registry cases,
including methods of reconciling possible matches.
5. Participating in a conference call (within one month of the
award) with CDC and other awardees to begin to develop a project plan
and 16-month timeline.
6. Collaborating with CDC staff members to develop data collection
forms for ancillary information about co-morbidities and barriers to
reporting lab results, as well as whether samples for CD4/VL testing
are drawn at post test counseling, possible reasons for no CD4/VL
testing, and the inability to link newly diagnosed persons to care.
7. Meeting with CDC. The area project collaborator will travel to
Atlanta for one meeting and participate in monthly conference calls
related to planning, coordinating, and conducting this project.
8. Transferring collected data to CDC monthly.
CDC Activities for this program are as follows:
1. Conduct a conference call, within one month of award, to develop
a project plan and time line for the collection and reporting of data
to CDC.
2. Support and assist training needed to conduct project including
monthly conference calls with awardees.
3. Collaborate with awardees to develop strategies for enhancing
surveillance activities that address barriers to reporting of
opportunistic infections, CD4, and viral load test results.
4. Receive data monthly, assess data quality, and store data in
secure environment.
5. Provide quarterly analytic progress reports to participating
areas.
6. Analyze data and write reports in collaboration with awardees.
II. Award Information
Type of Award: Cooperative agreement.
Fiscal Year Funds: 2005.
Approximate Total Funding: $500,000 (This amount is an estimate,
and is subject to availability of funds.)
Approximate Number of Awards: Five to Seven.
Approximate Average Award: $100,000 (This amount is for the first
12-month budget period, and includes both direct and indirect costs.)
Floor of Award Range: $75,000.
Ceiling of Award Range: $125,000.
Anticipated Award Date: August 31, 2005.
Budget Period Length: Four months.
Project Period Length: 16 months. Throughout the project period,
CDC's commitment to continuation of awards will be conditioned on the
availability of funds, evidence of satisfactory progress by the
recipient (as documented in required reports), and the determination
that continued funding is in the best interest of the federal
government.
III. Eligibility Information
III.1. Eligible Applicants
1. Eligible applicants are state or territorial health departments
or directly funded city health departments currently engaged in HIV/
AIDS surveillance funded through Program Announcement 04017. Eligible
applicants must have reported a minimum of 500 HIV and AIDS cases in
2003, of which at least 300 are HIV cases, as reflected in Volume 15
(Tables 14 and 16) of the CDC HIV/AIDS Surveillance Report. Single
reporting areas that do not have sufficient cases may form a consortium
with an adjoining area or areas so that the combined total number of
HIV and AIDS cases is at least 500, of which at least 300 are HIV cases
reported in 2003. Areas wishing to collaborate must designate a lead
grantee for protocol implementation, data collection, communication,
and coordination of financial remuneration.
2. Eligible applicants must be located in areas where persons of
color (Asian, Pacific Islanders, Black, American Indian/Alaskan Native,
Hispanic and Multiracial) comprise more than 30 percent of new HIV/AIDS
cases with known race/ethnicity.
Known eligible areas include: Alabama, Arizona, Colorado, Florida,
Houston, Indiana, Louisiana, Michigan, Mississippi, Missouri, New
Jersey, New York, New York City, North Carolina, Ohio, Pennsylvania,
Puerto Rico, South Carolina, Tennessee, Texas, and Virginia.
Eligible areas are restricted to those with confidential, name-
based HIV (with or without AIDS at the time of diagnosis) reporting
(those submitting HIV data to CDC) because this project will augment
surveillance data with complete laboratory data and other sources of
surveillance data where the use of name is the most accurate method to
link HIV surveillance data to supplemental data. Furthermore, to most
efficiently use available resources, the standard surveillance software
will be used and only those areas with confidential, name-based
reporting currently submit both HIV and AIDS data to CDC.
[[Page 38941]]
In each area, HIV morbidity must be sufficient to allow for
adequate sample sizes therefore, annual reported cases to CDC will be
used as a criterion for eligibility. The sizes of the samples must be
large enough to be able to detect HIV opportunistic infections which
are uncommon.
Eligible applicants must have reported to the CDC HIV/AIDS
reporting system a minimum of 500 HIV and AIDS cases in 2003, of which
at least 300 are HIV cases, as reflected in Volume 15 (Tables 14 and
16) of the CDC HIV/AIDS Surveillance Report. Single reporting areas
that do not have sufficient cases may form a consortium with an
adjoining area or areas so that the combined total number of HIV and
AIDS cases is at least 500, of which at least 300 are HIV cases
reported in 2003.
Eligible applicants are areas where persons of color (Asian,
Pacific Islanders, Black, American Indian/Alaskan Native, Hispanic and
Multiracial) comprise >=30% of new HIV/AIDS cases with known race/
ethnicity. Because a limited number of sites will be funded, racial and
ethnic diversity of cases among each of the participating sites will be
required to ensure a measure of representation of national data.
III.2. Cost Sharing or Matching
Matching funds are not required for this program.
III.3. Other
CDC will accept and review applications with budgets greater than
the ceiling of the award range.
Special Requirements: If the application is incomplete or non-
responsive to the special requirements listed in this section, it will
not be entered into the review process. The applicant will be notified
the application did not meet submission requirements.
Late applications will be considered non-responsive. See
section ``IV.3. Submission Dates and Times'' for more information on
deadlines.
Note: Title 2 of the United States Code Section 1611
states that an organization described in Section 501(c)(4) of the
Internal Revenue Code that engages in lobbying activities is not
eligible to receive Federal funds constituting an award, grant, or
loan.
The following are general considerations that will affect decisions
on funding levels. At least one unique reporting area for each of the
following categories should be funded:
Separate laboratory results database that complements the
national HIV/AIDS surveillance system data. Areas have received,
entered, and maintained CD4 counts, with or without VL values, for HIV/
AIDS registry cases, in a separate laboratory database for a period of
not less than one year from application date. This activity should be
ongoing, with plans to further expand capacity, including VL reporting
if this is not already being conducted. Areas that have not routinely
uploaded CD4 counts to the national HIV/AIDS surveillance system will
be required to do so. Source of lab results (e.g., electronic lab
reporting, results received on paper, medical record extraction, etc.)
will be recorded.
More than 55 percent of the area's combined HIV and AIDS
cases have at least one CD4 count within 12 months of initial HIV
diagnosis. At least one CD4 count, obtained within 12 months following
the initial diagnosis, was reported for most (greater than 55 percent)
of the combined HIV and AIDS cases diagnosed in 2002 and 2003. This
information should have been transmitted to CDC as part of the national
HIV/AIDS surveillance system. Areas may average two years of diagnostic
data to reach the 55 percent prevalence estimate, if each year's cases
do not exceed 55 percent.
Current participant in the Morbidity Monitoring Project.
Not all cases enrolled in the Morbidity Monitoring Project (MMP),
formerly announced as the Morbidity and Risk Behavior Surveillance
Project, will be eligible for this project. Systematic sampling of
newly diagnosed cases will be used to identify the population for
ALOHA. At a minimum, include 500 HIV/AIDS cases annually, of which no
less than 300 cases were initially diagnosed with HIV only. All cases
included in ALOHA will require medical record abstraction and possible
case follow-up. Cases enrolled in both the MMP and ALOHA will be
identified as such.
Experience conducting large electronic database matching
to HIV/AIDS case registry. Areas will be required to match to another
database to add comprehensive OI and co-morbidity information to their
HIV/AIDS case registry. OIs will be limited to those diagnosed six
months before and after initial HIV diagnosis. Database areas may match
to include infectious disease (e.g., NEDSS; hepatitis, cancer or
tuberculosis registries), prescription medication databases (e.g.,
Medicaid; AIDS Drug Assistance Program; etc.), or other databases with
similar information. It may be necessary to match to multiple databases
to provide a comprehensive review of OIs for a newly diagnosed case.
The participating HIV/AIDS surveillance program will need a memorandum
of understanding or similar written agreement with the program that
manages the matched-to database. Case follow-up that examines periods
of antibiotic/antiviral use should provide information about
opportunistic infections being treated, if this is not obvious from the
class of medication.
IV. Application and Submission Information
IV.1. Address to Request Application Package
To apply for this funding opportunity, use application form CDC
5161-1.
Electronic Submission: CDC strongly encourages the applicant to
submit the application electronically by utilizing the forms and
instructions posted for this announcement on http://www.Grants.gov, the
official Federal agency wide E-grant Web site. Only applicants who
apply on-line are permitted to forego paper copy submission of all
application forms.
Paper Submission: Application forms and instructions are available
on the CDC Web site, at the following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm
.
If access to the Internet is not available, or if there is
difficulty accessing the forms on-line, contact the CDC Procurement and
Grants Office Technical Information Management Section (PGO-TIM) staff
at 770-488-2700 and the application forms can be mailed.
IV.2. Content and Form of Submission
Application: A project narrative must be submitted with the
application forms. The narrative must be submitted in the following
format:
Maximum number of pages: 15 pages. If the narrative
exceeds the page limit, only the first pages that are within the page
limit will be reviewed.
Font size: 12 point unreduced
Line spacing: Double-spaced
Paper size: 8.5 by 11 inches
Page margin: One inch
Printing: Only on one side of page
Binding: Hold document together only by rubber bands or
metal clips; do not bind document in any other way.
The narrative should address activities that will be conducted over
the entire project period, and must include the following items in the
order listed:
Program Plan
Objectives
Understanding
Methods
Performance Measures
Budget Justification (not included in the narrative page
limitation)
[[Page 38942]]
Additional information may be included in the application
appendices. The appendices will not count toward the narrative page
limit. This additional information includes:
State laboratory reporting laws
Evidence of legal authority to follow-up, and abstract
medical records
State specific statistics to support application
Curriculum Vitas or Resumes
The agency or organization is required to have a Dun and Bradstreet
Data Universal Numbering System (DUNS) number to apply for a grant or
cooperative agreement from the Federal government. The DUNS number is a
nine-digit identification number, which uniquely identifies business
entities. Obtaining a DUNS number is easy and there is no charge. To
obtain a DUNS number, go to http://www.dunandbradstreet.com or call 1-
866-705-5711.
For more information, see the CDC Web site at: http://www.cdc.gov/od/pgo/funding/pubcommt.htm
.
If the application form does not have a DUNS number field, please
write the DUNS number at the top of the first page of the application,
and/or include the DUNS number in the application cover letter.
Additional requirements that may require submittal of additional
documentation with the application are listed in section ``VI.2.
Administrative and National Policy Requirements.''
IV.3. Submission Dates and Times
Application Deadline Date: August 5, 2005.
Explanation of Deadlines: Applications must be received in the CDC
Procurement and Grants Office by 4 p.m. Eastern Time on the deadline
date.
Applications may be submitted electronically at http://www.grants.gov.
Applications completed on-line through Grants.gov are
considered formally submitted when the applicant organization's
Authorizing Official electronically submits the application to http://www.grants.gov
.
Electronic applications will be considered as having met the
deadline if the application has been submitted electronically by the
applicant organization's Authorizing Official to Grants.gov on or
before the deadline date and time.
If submittal of the application is done electronically through
Grants.gov (http://www.grants.gov), the application will be
electronically time/date stamped, which will serve as receipt of
submission. Applicants will receive an e-mail notice of receipt when
CDC receives the application.
If submittal of the application is by the United States Postal
Service or commercial delivery service, the applicant must ensure that
the carrier will be able to guarantee delivery by the closing date and
time. If CDC receives the submission after the closing date due to: (1)
Carrier error, when the carrier accepted the package with a guarantee
for delivery by the closing date and time, or (2) significant weather
delays or natural disasters, the applicant will be given the
opportunity to submit documentation of the carrier's guarantee. If the
documentation verifies a carrier problem, CDC will consider the
submission as having been received by the deadline.
If a hard copy application is submitted, CDC will not notify the
applicant upon receipt of the submission. If questions arise on the
receipt of the application, the applicant should first contact the
carrier. If the applicant still has questions, contact the PGO-TIM
staff at (770) 488-2700. The applicant should wait two to three days
after the submission deadline before calling. This will allow time for
submissions to be processed and logged.
This announcement is the definitive guide on application content,
submission address, and deadline. It supersedes information provided in
the application instructions. If the submission does not meet the
deadline above, it will not be eligible for review, and will be
discarded. The applicant will be notified the application did not meet
the submission requirements.
IV.4. Intergovernmental Review of Applications
Your application is subject to Intergovernmental Review of Federal
Programs, as governed by Executive Order (EO) 12372. This order sets up
a system for state and local governmental review of proposed federal
assistance applications. You should contact your state single point of
contact (SPOC) as early as possible to alert the SPOC to prospective
applications, and to receive instructions on your state's process. To
get the current SPOC list, go to http://www.whitehouse.gov/omb/grants/spoc.html
.
IV.5. Funding Restrictions
The following restrictions must be taken into account while writing
your budget:
Funds may not be used for research.
Reimbursement of pre-award costs is not allowed.
If requesting indirect costs in the budget, a copy of the indirect
cost rate agreement is required. If the indirect cost rate is a
provisional rate, the agreement should be less than 12 months of age.
Guidance for completing the budget can be found on the CDC Web
site, at the following Internet address: http://www.cdc.gov/od/pgo/funding/budgetguide.htm
.
IV.6. Other Submission Requirements
Application Submission Address: Electronic Submission: CDC strongly
encourages applicants to submit applications electronically at http://www.Grants.gov The application package can be downloaded from http://www.Grants.gov.
Applicants are able to complete it off-line, and then
upload and submit the application via the Grants.gov Web site. E-mail
submissions will not be accepted. If the applicant has technical
difficulties in Grants.gov, customer service can be reached by e-mail
at http://www.grants.gov/CustomerSupport or by phone at 1-800-518-4726
(1-800-518-GRANTS). The Customer Support Center is open from 7 a.m. to
9 p.m. Eastern Time, Monday through Friday.
CDC recommends that submittal of the application to Grants.gov
should be early to resolve any unanticipated difficulties prior to the
deadline. Applicants may also submit a back-up paper submission of the
application. Any such paper submission must be received in accordance
with the requirements for timely submission detailed in Section IV.3.
of the grant announcement. The paper submission must be clearly marked:
``BACK-UP FOR ELECTRONIC SUBMISSION.'' The paper submission must
conform to all requirements for non-electronic submissions. If both
electronic and back-up paper submissions are received by the deadline,
the electronic version will be considered the official submission.
It is strongly recommended that the applicant submit the grant
application using Microsoft Office products (e.g., Microsoft Word,
Microsoft Excel, etc.). If the applicant does not have access to
Microsoft Office products, a PDF file may be submitted. Directions for
creating PDF files can be found on the Grants.gov Web site. Use of file
formats other than Microsoft Office or PDF may result in the file being
unreadable by staff.
or
Paper Submission: Applicants should submit the original and two
hard copies of the application by mail or express delivery service to:
Technical Information Management--RFA AA120, CDC Procurement
and Grants
[[Page 38943]]
Office, 2920 Brandywine Road, Atlanta, GA 30341.
V. Application Review Information
V.1. Criteria
Applicants are required to provide measures of effectiveness that
will demonstrate the accomplishment of the various identified
objectives of the cooperative agreement. Measures of effectiveness must
relate to the performance goals stated in the ``Purpose'' section of
this announcement. Measures must be objective and quantitative, and
must measure the intended outcome. These measures of effectiveness must
be submitted with the application and will be an element of evaluation.
The application will be evaluated against the following criteria:
1. Methods (30 points)
The extent to which the applicant demonstrates the technical
capability to conduct the project using appropriate data collection and
analytic methods for the following:
a. Accurately linking incoming lab results to all HIV and AIDS
cases.
b. Transmitting that information to the national HIV/AIDS
surveillance system for the duration of ALOHA.
c. Conducting active surveillance and medical record abstraction,
including CD4 and VL results, OIs, and ancillary information, following
a protocol developed in collaboration with CDC.
d. Conducting active, ongoing follow-up of cases.
e. Documenting methods for linking lab results to registry cases,
including methods of reconciling possible matches.
f. Describing specific activities in support of the general funding
considerations (Section III.3., bullets 1-4).
2. Understanding of Project Objectives (25 points)
The applicant's understanding of ALOHA objectives and the
applicant's specific role in achieving those objectives.
3. Performance Measures (20 points)
The applicant's ability to evaluate progress, including:
a. Measures of success in improving CD4, VL, and OI ascertainment
and their impact on overall reporting, compared with cases diagnosed in
calendar year 2004.
b. Documenting collaboration with CDC staff to develop data
collection forms for ancillary information about co-morbidities,
barriers to reporting lab results, whether samples for CD4/VL testing
are drawn at post test counseling, possible reasons for no CD4/VL
testing, and the inability to link newly diagnosed persons to care.
c. Transfer data collected to CDC on a monthly basis.
4. Program Plan (15 points)
Applicants must demonstrate that they meet the eligibility
criteria. Applicants must indicate the general consideration (Section
III.3., bullets 1-4) under which they want to be evaluated (choose only
one) and provide supporting documentation, as needed. Is the plan
adequate to carry out the proposed objectives? How complete and
comprehensive is the plan for the entire project period? Does the plan
include quantitative process and outcome measures?
5. Objectives (10 points)
The extent to which the objectives are specific (with time frames),
realistic, and address the required recipient activities.
6. Budget Justification (Reviewed, but not scored).
The extent to which the budget is reasonable, clearly justified,
and consistent with the intended use of funds. All budget categories
should be itemized.
V.2. Review and Selection Process
Applications will be reviewed for completeness by the Procurement
and Grants Office (PGO) staff, and for responsiveness by NCHSTP.
Incomplete applications and applications that are non-responsive to the
eligibility criteria will not advance through the review process.
Applicants will be notified that their application did not meet
submission requirements.
An objective review panel will evaluate complete and responsive
applications according to the criteria listed in the ``V.1. Criteria''
section above. The objective review process will follow the policy
requirements as stated in the GPD 2.04 [http://198.102.218.46/doc/gpd204.doc
].
Applications will be funded according to their score and rank,
which will be determined by the review panel. All persons serving on
the panel will be external to the funding division of NCHSTP. In
addition, the following factor may affect the funding decision: At
least one applicant should be funded in each of the four general
consideration areas (See Section III.3., bullets 1-4).
CDC will provide justification for any decision to fund out of rank
order.
V.3. Anticipated Award Date
August 31, 2005.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a Notice of Award (NoA) from the
CDC Procurement and Grants Office. The NoA shall be the only binding,
authorizing document between the recipient and CDC. The NoA will be
signed by an authorized Grants Management Officer, and mailed to the
recipient fiscal officer identified in the application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.
VI.2. Administrative and National Policy Requirements
Successful applicants must comply with the administrative
requirements outlined in 45 CFR Part 74 and Part 92 as Appropriate. The
following additional requirements apply to this project:
AR-4 HIV/AIDS Confidentiality Provisions
AR-5 HIV Program Review Panel Requirements
AR-7 Executive Order 12372
AR-8 Public Health System Reporting Requirements
AR-9 Paperwork Reduction Act Requirements
AR-10 Smoke-Free Workplace Requirements
AR-11 Healthy People 2010
AR-12 Lobbying Restrictions
AR-14 Accounting System Requirements
AR-25 Release and Sharing of Data
Additional information on these requirements can be found on the
CDC web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm
.
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
An additional Certifications form from the PHS5161-1 application
needs to be included in the Grants.gov electronic submission only.
Applicants should refer to http://www.cdc.gov/od/pgo/funding/PHS5161-1-Certificates.pdf.
Once the applicant has filled out the form, it should
be attached to the Grants.gov submission as Other Attachments Form.
VI.3. Reporting Requirements
You must provide CDC with an original, plus two hard copies of the
following reports:
1. Interim progress report, due no less than 90 days before the end
of the
[[Page 38944]]
budget period. The progress report will serve as your non-competing
continuation application, and must contain the following elements:
a. Current Budget Period Activities Objectives.
b. Current Budget Period Financial Progress.
c. New Budget Period Program Proposed Activity Objectives.
d. Budget.
e. Measures of Effectiveness.
f. Additional Requested Information.
2. Annual progress report, due 90 days after the end of the budget
period.
3. Financial status report, no more than 90 days after the end of
the budget period.
4. Final financial and performance reports, no more than 90 days
after the end of the project period.
VII. Agency Contacts
We encourage inquiries concerning this announcement. For general
questions, contact: Technical Information Management Section, CDC
Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341,
Telephone: 770-488-2700.
For program technical assistance, contact: Debra Hayes-Hughes,
Project Officer, Centers for Disease Control and Prevention, 1600
Clifton Road, NE., MS E-47, Atlanta, GA 30333, Telephone: 404-639-4493,
E-mail: DHayes-Hughes@cdc.gov.
For financial, grants management, or budget assistance, contact:
Kang Lee, Grants Management Specialist, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta, GA 30341, Telephone: 404-498-
1917, E-mail: kil8@cdc.gov.
VIII. Other Information
This and other CDC funding opportunity announcements can be found
at http://www.cdc.gov. Click on ``Funding,'' then ``Grants and
Cooperative Agreements.''
Dated: June 28, 2005.
Alan A. Kotch,
Acting Deputy Director, Procurement and Grants Office, Centers for
Disease Control and Prevention.
[FR Doc. 05-13223 Filed 7-5-05; 8:45 am]
BILLING CODE 4163-18-P